Viatris Inc. (vtrs)
VTRS — Company Overview
Investors tracking VTRS follow a Drug Manufacturers - Specialty & Generic name listed on NMS within Healthcare.
| Ticker | VTRS |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | NMS |
| Market cap | $19.66B |
| Last price | $17.12 |
| Size category | Large Cap |
VTRS — Business Description
The business profile of Viatris Inc. (VTRS) reflects its role in Drug Manufacturers - Specialty & Generic. Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such…
Official website: https://www.viatris.com.
VTRS — Investment Thesis
Viatris Inc. (VTRS) attracts investors weighing Drug Manufacturers - Specialty & Generic fundamentals against current market pricing.
- Revenue is expanding at roughly 4.9% year-over-year (public data).
- Dividend yield near 2.8% adds an income component to total return.
- Equity market capitalization is approximately $19.66B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
VTRS — Financial Health
VTRS financial profile reflects operating efficiency and capital structure using available market fundamentals.
Negative profit margin (-2.8%) signals near-term profitability pressure. Positive free cash flow of $2.68B supports balance-sheet flexibility.
| Forward P/E | 6.40× |
| Price / Sales | 1.33× |
| Price / Book | 1.36× |
| Gross margin | 40.3% |
| Operating margin | 12.6% |
| Profit margin | -2.8% |
| Return on equity | -2.8% |
| Debt / Equity | 95.53 |
| Free cash flow | $2.68B |
VTRS — Growth Outlook
Growth outlook for Viatris Inc. (VTRS) depends on demand trends in Drug Manufacturers - Specialty & Generic and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 4.9% suggests steady but measured expansion.
- Price is 6.9% below the 52-week high.
VTRS — Competitive Position
Viatris Inc. (VTRS) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Drug Manufacturers - Specialty & Generic.
- Market capitalization of $19.66B places VTRS among large-cap peers.
- Gross margin near 40.3% may reflect pricing power or favorable mix.
VTRS — Strengths
Strengths for Viatris Inc. (VTRS) inferred from public financial metrics:
- Gross margin of 40.3% supports competitive unit economics.
- Positive free cash flow ($2.68B).
- Dividend yield of 2.8% for income-oriented holders.
- Large Cap scale ($19.66B) may provide distribution and funding advantages.
- Price near 52-week highs — positive price momentum on public markets.
VTRS — Weaknesses
Weaknesses and pressure points for Viatris Inc. (VTRS) based on available data:
- Thin profit margin (-2.8%).
VTRS — Opportunities
- Dividend yield of 2.8% appeals to total-return investors.
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
VTRS — Risks
- Thin margins leave less room for operational missteps.
VTRS — Summary
Viatris Inc. (VTRS) is a large-cap Healthcare company focused on Drug Manufacturers - Specialty & Generic, listed on NMS. Last price $17.12 with market cap $19.66B. Revenue grew 4.9% year-over-year per public data. Notable strengths include gross margin of 40.3% supports competitive unit economics. Key watch items include thin profit margin (-2.8%). Review free estimates and earnings pages for VTRS; upgrade for institutional ownership and live headlines.
Start Free — open VTRS in Vest Terminal
Access live data, filings, ownership, and analysis for Viatris Inc..
Viatris Inc. FAQ
What does Viatris Inc. (VTRS) do?
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater Ch…
What is VTRS's P/E ratio?
Viatris Inc. has a trailing P/E of N/A× based on publicly available market data.
Does VTRS pay a dividend?
Indicated dividend yield: 2.8%. Confirm ex-dates and payout history in Vest Terminal.
What sector is VTRS in?
Viatris Inc. is classified in Healthcare (Drug Manufacturers - Specialty & Generic) on NMS.
What is VTRS's market capitalization?
Approximate market cap: $19.66B.
What are the main risks for VTRS?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of VTRS?
Potential positives include gross margin of 40.3% supports competitive unit economics, positive free cash flow ($2.68b).
Where can I get analyst estimates for VTRS?
Public analyst price targets and consensus for Viatris Inc. are on the free /stocks/vtrs/estimates page. Deeper estimate history and models are available in Vest Terminal.